Company Overview and News
Start-ups in Asia-Pacific have received US$4.8b, or over 60pc of the world’s proptech investments, with Hong Kong and China taking US$3b of that amount
The company is putting the Cityplaza Three and Cityplaza Four towers on the market amid strong demand for office space in the city
Swire Properties said retail sales at the shopping malls under its management gained in the first three months of the year, as increasing tourist arrivals spilled over to higher shopping bills.
Analysts say pop-up stores allow retailers and mall operators to gather customers’ response quickly and adjust their business plans to capture opportunities
The following slide deck was published by Swire Properties Ltd. ADR in conjunction with their 2017 Q4 earnings call.
Underlying profit of HK$4.74 billion last year was still lower than the HK$5.27 billion forecast by analysts
City launches a certification scheme for green bonds amid calls for it to use its expertise in financial services to help develop the market
A total of 63 Fortune 500 companies occupy about 2.2m sq ft of office spaces in Hong Kong East
The company has agreed to take a 50 per cent interest in a Shanghai retail development project in Pudong for US$214m
Started in 1870 as a small branch of its UK parent, Swire Pacific is a major player in property, beverages, aviation, marine services and trading and industries
Analysts say the task has been cut out for Merlin Bingham Swire, who takes over as chairman of the group’s Asian holding unit and property subsidiary on July 1
John Slosar, who will retire from the Swire Group on July 1, will remain as chairman of Cathay Pacific Airways to guide the carrier’s transformation plan.
Multinationals are moving out of Central Hong Kong in their droves in search of twice the spec, at half the cost
Firms are leaving Central for the city’s outer areas in pursuit of digitalisation, millennial talent and cost benefits
Shared space can be a viable alternative for companies in the world’s most expensive location for conventional offices, according to research
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...